Ake­so re­ports an­oth­er Phase 3 win for PD-1xVEGF ap­proach in lung can­cer

Ake­so said its PD-1xVEGF bis­pe­cif­ic an­ti­body ivonescimab beat BeiGene’s PD-1 block­er Tevim­bra in a Phase 3 study in lung can­cer pa­tients in Chi­na.

The read­out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER